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Background: Pneumonia and diarrhea are leading causes of death for children under five (U5). It is challenging to
estimate the total number of deaths and cause-specific mortality fractions. Two major efforts, one led by the Institute
for Health Metrics and Evaluation (IHME) and the other led by the World Health Organization (WHO)/Child Health
Epidemiology Reference Group (CHERG) created estimates for the burden of disease due to these two syndromes, yet
their estimates differed greatly for 2010.
Methods: This paper discusses three main drivers of the differences: data sources, data processing, and covariates used
for modelling. The paper discusses differences in the model assumptions for etiology-specific estimates and presents
recommendations for improving future models.
Results: IHME’s Global Burden of Disease (GBD) 2010 study estimated 6.8 million U5 deaths compared to 7.6 million U5
deaths from CHERG. The proportional differences between the pneumonia and diarrhea burden estimates from the
two groups are much larger; GBD 2010 estimated 0.847 million and CHERG estimated 1.396 million due to pneumonia.
Compared to CHERG, GBD 2010 used broader inclusion criteria for verbal autopsy and vital registration data. GBD 2010
and CHERG used different data processing procedures and therefore attributed the causes of neonatal death
differently. The major difference in pneumonia etiologies modeling approach was the inclusion of observational study
data; GBD 2010 included observational studies. CHERG relied on vaccine efficacy studies.
Discussion: Greater transparency in modeling methods and more timely access to data sources are needed. In
October 2013, the Bill & Melinda Gates Foundation (BMGF) hosted an expert meeting to examine possible approaches
for better estimation. The group recommended examining the impact of data by systematically excluding sources in
their models. GBD 2.0 will use a counterfactual approach for estimating mortality from pathogens due to specific
etiologies to overcome bias of the methods used in GBD 2010 going forward.* Correspondence: john.grove@gatesfoundation.org
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Historically, pneumonia and diarrheal disease are the lead-
ing causes of death for children under five (U5) worldwide
after neonatal causes [1-3]. However, accurate quantifica-
tion of cause-specific mortality fractions for pneumonia
and diarrheal diseases is difficult to achieve; current es-
timates vary substantially across modeling groups. Dif-
ferences in etiology-specific mortality estimates are of
considerable concern as global and national priorities
for interventions including vaccination campaigns, rou-
tine immunizations systems, and allocation of health
resources are informed by these estimates. The intro-
duction of the United Nations (UN) Millennium Develop-
ment Goals (MDGs) turned additional attention to the
need for improved burden of disease estimates to track
global and individual countries’ progress toward achieve-
ments in the reduction of child deaths [4]. These factors
have led to efforts in mathematical disease burden model-
ing to provide estimates of cause-specific disease morbid-
ity and mortality. Two major efforts have been undertaken
to address the shortcomings in this area, both building on
previous attempts at comprehensive estimates of disease
burden: 1) the Global Burden of Disease (GBD) 2010
study led by the Institute for Health Metrics and Evalu-
ation (IHME), and 2) the global pediatric disease burden
modeling work by the WHO and UNICEF/Child Health
Epidemiology Reference Group (CHERG).
The GBD 2010 study is led by IHME at the University
of Washington, Seattle, in partnership with the Imperial
College London, the University of Queensland, Harvard
University, and many other institutions, and its estimates
include total and cause-specific mortality for children
U5. IHME estimated the global and country-level U5
mortality from all causes, including acute respiratory in-
fections (ARI) that they further divided into lower and
upper respiratory infection (LRI and URI, respectively)
and diarrhea. Selected etiology-specific estimates of LRI
and diarrhea were also made at the country and global
levels. Only the global estimates are currently in the
public domain [5,6].
CHERG was established by WHO and UNICEF in 2001,
but is independent of the various WHO program areas.
CHERG has undertaken comprehensive disease burden
modeling of causes of death in children U5 and has pro-
vided sequential annual estimates from 2001 through
2011. During each revision, the CHERG model makes im-
provements and includes newly available data. In 2012,
CHERG published year 2010 causes of death, which built
upon previously models published in 2010. In 2013,
CHERG published year 2011 causes of death, as well as
estimates for selected etiologies of pneumonia and diar-
rhea [7-10].
In this paper we present an overview of the magnitude
of the differences between GBD 2010 and CHERGestimates of U5 mortality related to pneumonia and diar-
rhea, followed by a discussion of three broad areas that
may drive the variation in these estimates: data sources,
data processing, and the use of risk factor data (covari-
ates). Next, we present conceptual models for the two
groups’ pneumonia and diarrhea etiology models and dis-
cuss differences in the modeling assumptions. Finally, we
conclude with recommendations from an expert meeting,
hosted by the Bill & Melinda Gates Foundation (BMGF)
in October 2013, for improving the estimates for the up-
coming CHERG and GBD 2.0 publications.
Magnitude of the differences in U5 mortality
Both the GBD 2010 and the CHERG cause-specific mor-
tality estimation methods use total U5 mortality as the de-
nominator, but their sources for this denominator differ,
which has great influence on their final cause-specific esti-
mates. Tables 1, 2 and 3 show GBD 2010 and CHERG
estimates for year 2010 total U5 mortality due to pneu-
monia, diarrhea, and their etiologies. CHERG used the
Interagency Group for Child Mortality Estimation
(IGME) year 2010 U5 mortality estimate of 7.660 mil-
lion deaths [11] while GBD 2010 provided its own esti-
mate of 6.880 million deaths, a difference of nearly
760,000 deaths (11%).
Alkema and You examined possible factors that might
account for differences in the overall U5 mortality rate
produced in 2011 by IHME and IGME, assessing data
sources, inclusion and exclusion criteria, outlier adjust-
ment, model fitting, and covariate adjustment [12]. They
determined that the data used in the model were re-
sponsible for larger differences than the model struc-
tures themselves. The authors concluded that if the two
groups used the same data set in their separate models,
they would have generated very similar estimates [12].
Differences in overall U5 mortality account for only
some of the differences, as pneumonia and diarrhea
cause-specific mortality fractions differ greatly between
GBD 2010 and CHERG (Figures 1, 2 and 3, summarizing
some of the data of Additional files 1, 2 and 3). The fol-
lowing sections describe drivers of the differences in the
pneumonia and diarrhea mortality estimates.
Drivers of the differences: data sources
Differences in data sources are a major driver of differ-
ences in the pneumonia and diarrhea mortality esti-
mates. GBD 2010 and CHERG used different inclusion
criteria for their models.
GBD 2010
The GBD 2010 modeling process used the following
steps for pneumonia and diarrhea mortality estimation:
1) data identification, 2) data processing, 3) Cause of
Death Ensemble models (CODEm) for modeling acute
Table 1 Estimates of the global burden due to pneumonia and diarrhea in children under five in 2010 [6,7]
CHERG GBD 2010
Deaths (×1,000) % total U5 mortality Deaths (×1,000) % total U5 mortality % difference*
Total U5 mortality 7,622 100% 6,841 100% 11%
Pneumonia/LRI** U5 1,396 18.3% 847 12.4% 49%
Pneumonia/LRI** neonatal (0–27 days) 325 4.3% 194 2.8% 51%
Pneumonia/LRI** postneonatal 1,071 14.1% 654 9.6% 48%
Diarrhea U5 801 10.5% 666 9.7% 18%
Diarrhea neonatal (0–27 days) 50 0.7% 77 1.1% −43%
Diarrhea postneonatal 751 9.9% 589 8.6% 24%
*Percent difference calculated: (CHERG - GBD 2010)/((CHERG + GBD 2010)/2) × 100.
**LRI: Lower respiratory infection.
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portional model for dividing ARI into lower respiratory
infections (LRI) and upper respiratory infections (URI)
deaths, 5) DisMod-MR model for estimating deaths due
to LRI and diarrhea etiologies, and 6) CoDCorrect for
scaling cause-specific mortality fractions to sum to one
(Figure 4).
For ARI, GBD 2010 identified 2,725 data points of
vital registration (VR) data, 100 verbal autopsy (VA) data
points from multiple sites, and 17 data points of surveil-
lance data. For diarrhea they used 2,696 data points of
VR data and 264 data points from VA studies. A data
point refers to the mortality rate for a specific cause in
an individual country for a specific year. For example, if
there are vital registration data for Tanzania from 1993–
2003 available, this would account for 11 data points of
VR data. Despite identifying many data points, some
countries did not have any data available. In the CODEm
models used to estimate ARI and diarrheal deaths [13],
data were weighted based on their proximity to the
country for which they estimated the cause-specific mor-
tality fractions. In countries with data, the in-country
data is weighted at 90%, data from the region is weighted
at 9%, and data from the super-region is weighted at 1%.
In countries with no data, 70% of the weight is given to
data from the region and 30% of the weight is given to
data from the super-region [13]. GBD 2010’s regions and
super-regions group countries with similar epidemiologyTable 2 Estimates of the global burden due to pneumonia et
CHERG (2011)
Pneumonia/LRI etiology Deaths (×1,000) % U5 pne
All 1,257 100.0%
Pneumococcal pneumonia 412 32.7%
H. influenzae type B 197 15.7%
Respiratory syncytial virus - -
Influenza - -
Other lower respiratory infections - -and economic development (e.g., high income countries
were grouped together), in addition to geographic prox-
imity. In this way, the model borrows data from neigh-
boring countries in the region and super-region to fill in
gaps where data are sparse.
GBD 2010 developed ARI and diarrhea cause of death
models using all VR data, regardless of the level of regis-
tration completeness, and also developed models restrict-
ing the inclusion of VR data based on the level of
registration ≥70%, ≥60%, ≥50%, ≥40%, and ≥30% com-
pleteness thresholds. All VA studies were considered for
inclusion in GBD 2010 cause of death models for ARI and
diarrhea. GBD 2010 researchers found very little differ-
ence in estimated U5 mortality due to ARI and diarrhea
between the model including all VR data and the model
that only included VR data that was at least 70% complete.
The final model included all VR data that was at least 60%
complete.
LRI deaths were further divided into five etiologies.
LRI etiology models used data from existing systematic
reviews and a database of published studies of ARI com-
piled by the WHO [14-16]. GBD 2010 included all studies
from these reviews after applying additional exclusion
criteria (details of the search strategy are available in
Additional file 4, supplementary materials). An add-
itional systematic search was conducted using the same
inclusion and exclusion rules for studies published be-
tween 2006–2011, which identified an additional 54iologies in children under five in 2010/2011 [6,9]
GBD 2010
umonia mortality Deaths (×1,000) % U5 LRI mortality
847.1 100.0%
168 19.8%
184 21.7%
234 27.6%
119 14.0%
143 16.9%
Table 3 Estimates of the global burden due to diarrhea etiologies in children under five in 2010/2011 [6,10]
CHERG (2011) GBD 2010
Diarrhea etiology Deaths (×1,000) % U5 diarrhea mortality Deaths (×1,000) % U5 diarrhea mortality
Total 712* 100% 666* 100%
Cholera** 9 1.3% 42.5 6.4%
Other salmonella infections 29 4.4%
Shigellosis 28 3.9% 43.6 6.5%
Enteropathogenic E. coli infection 79 11.1% 72.8 10.9%
Enterotoxigenic E. coli infection 42 6.0% 38.7 5.8%
Campylobacter enteritis 22 3.2% 63.6 9.5%
Amoebiasis 9.2 1.4%
Cryptosporidiosis 14 2.0% 83 12.5%
Rotaviral enteritis 197 27.8% 173 26.0%
Other diarrheal diseases 109 16.4%
Calicivirus 71 9.9%
Astrovirus 15 2.1%
Adenovirus 22 3.1%
All Salmonella 18 2.5%
Giardia lamblia 16 2.3%
Entamoeba histolytica 1 0.2%
Unknown etiology 176 24.5%
*CHERG death estimates sum up to 710,000 and those of GBD2010 to 664,000 due to rounding adjustments of individual figures.
**CHERG cholera estimate only represents Vibrio Cholera O1.
Figure 1 Percent difference in IGME vs. GBD 2010 estimated U5 deaths, 2010.
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Figure 2 Percent difference in CHERG vs. GBD 2010 estimated U5 pneumonia deaths, 2010.
Figure 3 Percent difference in CHERG vs. GBD 2010 estimated U5 diarrhea deaths, 2010.
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Figure 4 GBD 2010 analytical approach for estimating the global mortality burden due to LRI, diarrhea and their etiologies.
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available in Additional file 4, supplementary materials)
[6]. Forty-pneumonia deaths were due to pneumococ-
cus andefficacy studies were used in the GBD 2010 LRI
etiology models. (Additional file 2 lists all studies used
to model pneumonia etiologies by both GBD 2010 and
CHERG).
The GBD 2010 diarrhea etiology models included 189
studies from 1975–2010, with rotavirus-related data pro-
viding the largest number of studies at 126 (details of
the search strategy are available in the supplementary
materials and a comprehensive list of all studies used by
both CHERG and GBD 2010 is available in Additionalfile 3) [6]. Similar to the CODEm models, the modeling
procedure for LRI and diarrhea etiology models used hi-
erarchal spatial effects by which country models were
informed by data from the country, region, and super-
region only. Additionally, the models were age integrated
and therefore the models for U5 mortality were in-
formed only by data using the same age ranges in the
observational studies.
CHERG
The CHERG approach used the following steps 1) data
source identification, 2) data processing, 3) use of one of
three models to estimate neonatal and postneonatal
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profile, and data availability, 4) development of a disease-
specific model to estimate neonatal pneumonia and
tetanus, as well as measles and pertussis among older chil-
dren, and 5) adjusting deaths to sum to the total U5 mor-
tality (Figure 5) [6].
To estimate the total number of deaths due to pneu-
monia and diarrhea, CHERG used VR data if the coun-
try reported >80% VR coverage, had low U5 mortality
(defined as ≤35 deaths per 1,000 live births) and the data
were of high quality (defined as having a plausible distri-
bution of deaths by cause and limited use of improbable
causes of death, or if the causes of death could be catego-
rized for analysis). The vital registration multi-cause
model (VRMCM) model for postneonates (children 1–59
months of age) included data from 56 countries for a total
of 578 data points.
To estimate the total number of deaths in countries with
high mortality and low VR coverage, CHERG identified
VA studies using systematic literature reviews. Studies for
estimating deaths in children 1–59 months had to be
community-based, include at least two causes of death, beFigure 5 CHERG analytical approach for estimating the burden of disconducted after 1979 for 12 months or a multiple of
12 months (due to the seasonality of many infectious
causes of death), document at least 25 deaths in children
U5, have each death counted only once, and have fewer
than 25% of deaths due to unknown causes [7]. This
process identified 74 studies from 33 countries for a total
of 113 data points. For the neonatal verbal autopsy
multi-cause model (VAMCM), VA studies were either
community- or hospital-based, conducted for at least
12 months, followed the child for 7 or 28 days after
birth, included four or more of the six modeled causes
of death, had fewer than 25% of deaths due to unknown
causes, and had cause of death (COD) assignment com-
pleted by a skilled birth attendant, post mortem, or VA
[17]. This process identified 89 studies in 34 high-mortality
countries. Neonatal pneumonia was modeled using a sep-
arate set of 36 studies in which neonatal pneumonia was
reported separately from other neonatal infections or
causes of respiratory distress, although the clinical ability
to make this distinction is recognized as challenging [7].
To estimate the number of pneumonia deaths due to
pneumococcus and Haemophilus influenzae type B (Hib),ease in children under five in 2010 (adapted from Black 2010).
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conducted by O’Brien et al. [15] and Watt et al. [9,16].
O’Brien et al. used four vaccine trials to estimate mortality
due to pneumococcus [18-21]. A recently reported fifth
trial was added in the CHERG analysis (the COMPAS
trial) [22]. For Hib, Watt et al. [16] included four studies,
one each from the Gambia (individually randomized) [23],
Indonesia (cluster randomized) [24], Bangladesh (case
control) [25], and Chile (open cluster randomized) [26].
Rudan et al. [9] estimated the fraction of deaths due to
pneumococcus and Hib based upon the assumption that
the fraction of all cases due to each etiologic agent was
equal to the fraction of deaths due to that etiologic agent.
Through the systematic review they estimated that 33.0%
and 21.3% of pneumonia deaths were due to pneumococ-
cus and Hib, respectively [9].
To estimate the number of deaths due to diarrhea eti-
ologies, CHERG used studies conducted between 1991
and 2011 that lasted at least 12 months, involved chil-
dren U5 hospitalized for diarrhea, and tested all patients
or included a representative sample of hospitalized pa-
tients. Studies were excluded if they were conducted
during diarrheal outbreaks, did not differentiate between
inpatients and outpatients, only focused on special pop-
ulations, or did not use adequate laboratory techniques.
In total, 163 articles and 31 WHO Rotavirus Surveillance
Network data points were used in calculating etiology-
specific mortality.
Data sources discussion
The first major difference between the two groups’ ap-
proaches was their inclusion criteria for VR data. CHERG
only included data that were >80% complete, met a
threshold of adequate quality, and were from low U5 mor-
tality countries whereas the GBD 2010 final model only
included VR data that were >60% complete and did not
exclude VR data based on a country’s U5 mortality rate.
Therefore, VR data in both the CHERG and GBD 2010
models informed estimates in primarily lower mortality,
higher income countries where the burden due to pneu-
monia and diarrhea is generally lower. Tables 1, 2 and 3
and Additional file 1 present the differences in the esti-
mates based on these two approaches. The differences at
the country-level can be strikingly large. For example in
Nigeria, CHERG estimated 144,596 deaths due to pneu-
monia and GBD 2010 estimated 64,238 due to LRI in
2010, a 76% difference (Additional file 1).
The two approaches highlight the need to balance the
desire to increase the number of data points to inform the
models with concerns that incomplete data may contain
substantial biases. Bias is introduced by use of the VR
data, which represent populations that experience differ-
ent cause-specific mortality fractions than the population
that is not recorded by VR. By including incomplete VRdata, modelers run the risk of a biased representation of
the cause-specific mortality fractions for the entire popu-
lation. While the use of more data will increase the appar-
ent precision and narrow the uncertainty interval around
mortality estimates, the central estimate itself may be less
accurate (in terms of the estimate reflecting the “true”
cause-specific mortality fractions). In other words, if VR
systems systematically under- or over-report pneumonia
or diarrhea as a cause of death, this will not be captured in
the uncertainty interval. While theoretically a source of
potential bias, the sensitivity analyses conducted for the
GBD 2010 study showed that there was very little change
in the estimates, irrespective of what cut point was used
for VR data. This is partially due to few high pneumonia
and diarrhea burden countries providing any VR data in
the models.
The second major difference is that GBD 2010 included
observational studies to estimate the burden of pneumo-
nia according to specific etiologies, whereas CHERG relied
solely on the results of vaccine efficacy studies to produce
estimates. CHERG adopted a counterfactual approach and
estimated the fraction of radiologically confirmed pneu-
monia cases prevented by Hib and pneumococcal vaccines
in randomized trials (the vaccine probe approach) to esti-
mate total number of deaths due to Hib and pneumococ-
cal pneumonia. A counterfactual approach assesses what
would have happened in the absence of interventions to
prevent disease. This approach is strengthened when the
unvaccinated control group is large, as was the case in the
vaccine trials that contributed to the estimates. GBD 2010
used a categorical approach, and their methods operated
under the assumption that although trial data is superior
to observational data, the regional variation detected in
observational studies warranted their inclusion in the eti-
ology models. To correct for this difference in the quality
of the data, GBD 2010 included observational data, but
weighted the vaccine efficacy trial data by a factor of 10
[6]. CHERG’s methods did not include data from observa-
tional studies because observational studies lack sensitivity
for determining bacterial etiology and are non-specific for
determining viral etiology, and therefore tend to under-
estimate the contribution of bacterial pathogens and
overestimate the contribution of viral pathogens to
pneumonia mortality. These two approaches resulted in
vastly different global etiologic fractions of pneumonia
deaths due to pneumococcus: CHERG estimated 32.7%
and GBD 2010 estimated 19.8% (Table 2).
In addition, upon assessment of the data, CHERG
inferred that there is little evidence of regional variation
in etiologies, so the CHERG model assumed global
consistency in mortality due to pneumococcus and Hib
after adjustment for vaccine coverage. Finally, the CHERG
method inferred that trial data from Asia, Africa, North
America, and South America represent a wide range of
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highly unlikely that there is no regional variation in the
etiologies of pneumonia and diarrhea, but given a paucity
of quality data for the etiologies, estimating the regional
variation can be challenging. Thus far, modeling groups
have yet to develop methods to incorporate informative
observational studies while addressing their inherent
biases. Therefore, both approaches can lead to inaccurate
estimates; inclusion of observational data introduces sub-
stantial errors in etiologies, whereas restriction to vaccine
studies results in oversimplification.
Drivers of the differences: data processing
After data are selected for models, they are often proc-
essed to improve the validity of the data before model-
ing, including transformations, reassignment of cause of
death, and removal of outliers to improve the quality
and reduce the potential influence of a single or inaccur-
ate data point before modeling. Models that use the
same data but perform different transformations can
produce very different results.
Both GBD 2010 and CHERG improved the compar-
ability across different datasets by mapping older ver-
sions of the International Classification of Disease (ICD)
to the ICD-10 codes. GBD 2010 used a detailed algo-
rithm to reassign non-specific or undefined ICD codes,
referred to as “garbage codes,” (e.g., fever or cardiac ar-
rest) to logical causes of death. For example, 10.07% of
deaths attributed to the non-specific codes of fever, mal-
aise, febrile, and convulsions of unknown origin were
reassigned to LRI. Next, the dataset was split into 20
age/sex groups and the data were smoothed to account
for instances where specific deaths in a country were
very rare. Finally, the compiled dataset was assessed for
outliers. Outliers were defined using a subjective set of
criteria that were determined by subject-matter experts
as having a large inconsistency with other sources in the
same country or from the same region.
CHERG reassigned some non-specific COD codes for
neonates; classified all malnutrition deaths as “other
causes”; grouped neonatal deaths into one of six cat-
egories for estimates: preterm birth complications,
peripartum-related complications, infectious causes in-
cluding pneumonia, tetanus, sepsis, and meningitis,
congenital abnormalities, other neonatal disorders, and
diarrhea; and grouped deaths among children aged 1–
59 months into one of eight categories: pneumonia, in-
jury, malaria, meningitis, diarrhea, causes originating
from the perinatal period, congenital malformation, and
other causes.
GBD 2010 and CHERG took different approaches to
coding neonatal COD. Assignment of COD is particularly
difficult for neonates due to a lack of VA studies and the
general difficulty that clinicians have differentiating deathsdue to pneumonia, sepsis, and meningitis. GBD 2010 esti-
mated 732,000 deaths due to these three causes combined,
and similarly CHERG estimated 718,000 deaths. The two
groups differ, however, in how they split the deaths be-
tween the three causes: GBD 2010 attributed 193,131
(26%) deaths to pneumonia through their CODEm model;
CHERG used 36 studies to separate neonatal pneumonia
deaths from the broader category of neonatal infections
and estimated 325,000 (45%) deaths due to pneumonia.
The difference between the two groups’ estimates for neo-
natal pneumonia is 131,869 deaths or 24% of the differ-
ence between the two groups’ overall U5 pneumonia
mortality estimates.
Data processing discussion
Clearly, GBD 2010 and CHERG used different data pro-
cessing procedures and therefore attributed the causes
of neonatal death very differently. This is likely due to
the difficulty in assigning COD in neonates based on VA
studies and VR data. These differences in neonatal COD
assignments have large differences in the proportion of
neonatal infections attributed to pneumonia, which con-
sequently account for around a quarter of the difference
in the overall estimates for U5 pneumonia mortality.
This illustrates the role of subjective decision making in
situations where there is poor and limited data on COD.
With such little understanding about the causes of death
in neonates, there will be increased uncertainty around
the estimates. Furthermore, removal of outliers is a
problematic statistical technique that can introduce bias
into a dataset and subsequent model estimates. It is not
possible to evaluate which estimate is more accurate,
however this example highlights the importance of data
processing, how it can lead to large differences in the es-
timates, and the need for transparency about data pro-
cessing decisions.
Drivers of the differences: risk factor data
Given the paucity of data available for estimating the
mortality burden due to pneumonia and diarrhea in
many countries, both GBD 2010 and CHERG used data
on risk factors and correlates of pneumonia and diarrhea
(referred to as covariates by modelers) to further inform
their models in addition to regional/super-regional ef-
fects. Inclusion of covariates can improve a model’s ac-
curacy and precision in mortality estimates. A full list of
the covariates used by each modeling group is available
in Tables 4 and 5.
The inclusion of individual covariates can alter esti-
mates dramatically. For example, the CHERG model did
post-hoc adjustment for insecticide treated net (ITN)
coverage and Hib vaccine coverage in their VAMCM,
which modeled deaths in 79 high mortality countries
and excludes deaths due to measles and AIDS-mediated
Table 4 Covariates used to estimate pneumonia/LRI and its etiologies in children under five in 2010/2011 [6,7]
CHERG GBD 2010
Neonatal Postneonatal U5
Severe infection Pneumonia Lower respiratory
infection (LRI)
VRMCMa VAMCMb VRMCMa VAMCMb VRMCMa VAMCMb CODEmc
Covariates for
pneumonia/LRI
U5 mortality
Early neonatal: Neonatal mortality
rate
Early neonatal: Female literacy All model
covariatesd
All model
covariatesd
Health care access
Access to
antenatal care
DPT vaccination
coverage
Female literacy Low birth weight Hib3 vaccination coverage
(country-level)
Female literacy Quad-DPT
vaccination
coverage
Neonatal
mortality rate
Births with skilled
attendant
Access to sanitation
Indicator of the
EMRO region
Period
(early/late/overall)
Births with
skilled attendant
Tetanus toxoid
vaccine coverage
at birth
Access to water
Late neonatal: Indicator of the
EMRO region
Malnutrition in under 2
Female literacy Late neonatal: Education
U5 mortality rate Access to
antenatal care
Population density
Births with
skilled attendant
Indicator of the
EMRO region
Low birth
weight
General fertility
rate
Indicator of the
EMRO region
Births with
skilled attendant
Covariates for
pneumonia/LRI
etiologic fractions
Pneumococcal vaccination coverage Inpatient or outpatient/
community-based settings
(study-level)
Hib3 vaccination coverage
(country-level)
Health system access
(country-level)
aVital registration multi-cause model, bverbal autopsy multi-cause model, ccause of death ensemble model, dfor details, see Liu et al., Lancet, 2012 web appendices.
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when adjusted for both covariates was 23% compared to
20% when adjusting for only Hib vaccination in the
VAMCM. This demonstrates the power of adding a sin-
gle covariate to the model and its subsequent change to
the cause-specific mortality fractions.
While both GBD 2010 and CHERG examined many
covariates, there is little overlap between those included
in the two groups’ models. There are some potentially
influential covariates that were not included by either
group. For example, GBD 2010 did not include the per-
centage of population at risk for malaria for their pneumo-
nia or diarrhea models, but did include malaria risk in
their malaria model (Tables 4 and 5). CHERG included a
measure of population at risk for malaria as part of their
malaria equation in the VAMCM. This may be an import-
ant covariate to include in future studies, as malaria
deaths are often misattributed to pneumonia or diarrhea,
or pneumonia and diarrheal deaths are misattributed tomalaria [27,28]. Inclusion of malaria covariates could
increase the proportion of cases due to pneumonia and
diarrhea as control measures reduce malaria deaths. In
addition, numerous observational studies and meta-
analyses have noted that breastfeeding is associated
with reduced risk of both pneumonia and diarrhea
mortality [29-33]. The inclusion of the percentage of
women exclusively breastfeeding may improve model
predictions and therefore warrants consideration.
The reliance on covariate data in the absence of high
quality VA and VR COD data to predict mortality due to
pneumonia and diarrhea reinforces the need for quality
country-specific COD data and highlights the need for
better covariate data sources that measure target vari-
ables accurately. Additionally, there is a need for longitu-
dinal covariate data to assess trends in mortality due to
pneumonia and diarrhea. Regardless of the number of
covariates used, a modeling approach will never be as
accurate as estimating the burden of disease from high
Table 5 Covariates used to estimate diarrhea and its etiologies in children under five in 2010 [6,7]
CHERG GBD 2010
Neonatal Postneonatal U5
VRMCMa VAMCMb VRMCMa VAMCMb CODEmc
Covariates for
diarrhea U5
mortality
Diarrhea not estimated
in VRMCM due to few
diarrhea deaths
Neonatal
mortality rate
U5 population Mid study year Health care access
DPT
vaccination
coverage
Coverage of the third dose
of diphtheria pertussis and tetanus
vaccine (DPT3)
% urban population Rota virus coverage
Quad-DPT
vaccination
coverage
WHO Europe Region vs. other
WHO regions
U5 mortality rate Access to sanitation
Period (early/
late/overall)
Gross national income (per capita) Oral rehydration
therapy coverage
Access to water
Malnutrition in under 2
Education
Population density
GDP (lag-time)
Covariates for
diarrhea etiologic
fractions
n/a National coverage or
subnational but nationally
representative (study-level)
Inpatient or outpatient/
community-based settings
(study-level)
Number of pathogens
tested for (study-level)
Lag-distributed income
(country-level)
aVital registration multi-cause model, bverbal autopsy multi-cause model, ccause of death ensemble model.
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strong national systems.
Etiology model assumptions
Modeling the number and causal fractions of deaths due
to pneumonia and diarrhea etiologies is extremely diffi-
cult due to insensitive/incomplete diagnostics and the
lack of studies that provide estimates of the burden by
etiology. GBD 2010 estimated 21.7% and 19.8% com-
pared to CHERG’s estimated 15.7% and 32.7% of deaths
due to Hib and pneumococcus, respectively. Further-
more, GBD 2010 estimated that RSV was responsible for
27.6% of pneumonia deaths. Due to limitations in the
data available for estimating the etiologies of pneumonia
and diarrheal deaths, both GBD 2010 and CHERG made
several assumptions. Differences in assumptions and
their consequences may explain some of the differences
in the two groups’ estimates.
Pneumonia/LRI etiologies
To estimate the causal fraction and number of deaths
due to specific etiologies of pneumonia/LRI, GBD 2010
and CHERG both assumed that all cases admitted to
hospital were severe pneumonia cases, and that theetiologic proportion of chest radiography positive cases
was a reasonable surrogate for fatal cases in the commu-
nity. Both groups also assumed that in data from vaccine
efficacy trials, the fraction of radiologically confirmed
pneumonia cases that were assigned to Hib or pneumo-
coccus was a reasonable surrogate for that fraction in
fatal cases.
The groups differed in their assumptions on the pro-
portion of pneumonia due to different etiologies. GBD
2010 allowed for regional variation in the causal fraction
of pneumonia due to pneumococcus, Hib, RSV, influ-
enza virus, and other etiologies. This regional variation
was informed by 45 additional observational studies in-
cluded in their updated systematic review of the litera-
ture. In instances where children were found to have
multiple infections (e.g., pneumococcal pneumonia and
RSV), they used a probabilistic model to assign the etio-
logic fractions. The probabilistic model used the propor-
tion of pathogens in moderate to severe cases to assign
pneumonia etiologies to each death and the proportion
of pathogens in mild pneumonia to assign pneumonia
etiologies to each case. The model was not informed by
any hierarchy of causes of death. Children with no de-
tected pathogen were not included in the etiologic fraction
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formed by etiologic estimates, which assumed that the
proportion of deaths due to both pneumococcal pneumo-
nia and Hib did not vary by region (14–16). Instead, they
estimated one proportion for pneumococcus and one for
Hib and adjusted these proportions by the vaccine cover-
age for pneumococcus and Hib, respectively.
Both groups made assumptions about mortality due to
viral pneumonia specifically caused by influenza virus
and RSV. GBD 2010 built upon the work of Nair et al.
for both RSV and influenza mortality estimates by sup-
plementing those findings with data from observational
studies of viral etiologies. CHERG noted that the esti-
mates from two reviews of disease caused by RSV and
influenza virus, based on work conducted by Nair et al.
[34,35], could not provide point estimates or confidence
intervals, and consequently global and country-level etio-
logic estimates could not be made. Therefore, CHERG did
not make country-level mortality estimates for RSV and
influenza based on this study [9].
The two groups made different assumptions regarding
the patterns of mortality by age. For GBD 2010, DisMod-
MR, a multi-regression model used for etiology estimates,
enabled the cause-specific mortality fraction to vary with
age [36]. GBD 2010 made further assumptions regarding
the proportion of RSV; due to a lack of data for RSV, they
scaled the sum of the proportion of LRI due to RSV in
ages 2–4 years to 25% of the sum of the proportion in ages
0–1 year. This age difference was based on the pattern of
hospital admissions for RSV pneumonia observed in US
hospital data [6]. CHERG did not produce age-specific
mortality estimates beyond the number of deaths for
pneumococcal pneumonia and Hib in children U5.
Diarrhea etiologies
GBD 2010 and CHERG made several similar assump-
tions about diarrhea etiologies. Both assumed that hospi-
talized cases were more severe than those seen in the
community and that the etiologic proportions seen in se-
vere cases were representative of causes of diarrheal
deaths.
Both groups adjusted their etiologic fractions to sum
to one, which in effect allows only one etiology per diar-
rheal death, but the groups applied this constraint differ-
ently. GBD 2010 acted on this assumption in two ways:
1) where the cause of diarrheal death was unknown in a
study, GBD 2010 did not include this death in the de-
nominator when calculating the etiologic fractions and
instead assumed that the death was due to a completely
unknown etiology (i.e., an untested etiology); 2) when a
study detected multiple diarrheal pathogens, GBD 2010
used the proportion of pathogens in moderate to severe
cases to assign diarrheal etiologies to each death and the
proportion of pathogens in mild cases to assign diarrheaetiologies to each case, and did not use a hierarchy of
causes of death. CHERG reported both total age-adjusted
etiologic proportions (which summed to 138% of deaths)
and the proportions after scaling them to add to 100%.
They also allowed unknown pathogens to exist as a cat-
egory, but only used studies that examined eight or more
pathogens. Table 3 illustrates the differences in the cause-
specific mortality fractions for diarrheal deaths. The un-
known pathogen group accounted for 24.5% of deaths
after scaling. Direct comparison of the cause-specific mor-
tality fractions is difficult because CHERG generated esti-
mates for 13 pathogens while GBD 2010 generated
estimates for only ten pathogens, and the two groups’
pathogen lists do not completely overlap.
GBD 2010 used the assumption that there were regional
differences in the etiologic fractions and attempted to ac-
count for this with the country-specific covariates and by
varying the priors used in the Bayesian models. This en-
abled GBD 2010 to produce regional estimates of deaths
from each cause. Although CHERG did stratify the attrib-
utable fraction from each pathogen by WHO region, the
group did not consider there to be a sufficient number of
studies to draw conclusions from the estimates.
Etiologies discussion
The major difference in modeling approaches between
the two groups was inclusion of observational study data
for estimating pneumonia etiologies. GBD 2010 included
observational data, which showed regional variation, but
this regional variation may be due to less sensitive la-
boratory measures often used in observational studies.
Using observational studies relies on pneumonia diag-
nostics. Pneumonia etiologies are notoriously difficult to
diagnose because the gold standard of diagnosis is identifi-
cation of the pathogen from lung tissue. Given the inva-
siveness of this procedure, gold standard data are often
lacking. In addition, treatment with antibiotics before spe-
cimen collection can make isolation of the bacterial agent
difficult. Despite these limitations, observational studies
are more frequently conducted in more geographic re-
gions than expensive vaccine trials, and therefore provide
information about areas where vaccine trials are not feas-
ible. Given these factors, the GBD 2010 team utilized
observational studies to provide key data in building a
comprehensive understanding of mortality related to
pneumonia etiologies.
Estimating mortality due to the etiologies of pneumo-
nia and diarrhea relies on secondary endpoints and mul-
tiple assumptions about those endpoints. Specifically,
use of observational studies requires the assumption that
hospitalized cases represent severe cases, and the etiolo-
gies of severe cases match the etiologies of deaths. For
RSV, this assumption may be false, and many hospital-
ized RSV cases are not severe pneumonia cases. This
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RSV cases, and consequently an overestimation in the
number of RSV deaths. The use of vaccine probe studies
relies on the reduction of chest radiography confirmed
pneumonia as the measure of the reduction of cases due
to the specific pathogen in the vaccine. This counterfac-
tual approach can lead to the overestimation of the bur-
den due to specific pathogens if it is based on trial data
where the specific pathogen is more common, or can re-
sult in an underestimation if the trials are in areas where
the pathogen is less common.
Both groups also treated data points for U5 mortality
due to unknown and multiple pathogens differently. As
noted above, definitively identifying the causative diar-
rheal agent in stool is challenging because of the natural
carriage of organisms and the fact that it is common to
find multiple organisms in a single sample. For example,
the recent Global Enterics Multi-Center Study (GEMS)
found that 45% of diarrhea cases and 31% of non-
diarrheal controls had two or more potentially pathogenic
agents in their stool [37]. GBD 2010 excluded diarrheal
deaths with an unknown etiology. This may systematically
underestimate deaths from an etiology that is difficult to
detect and overestimate the contribution of other patho-
gens. By including unknown etiologies as a group, CHERG
avoids the problem of overestimation, but cannot address
the problem of underestimation. For deaths due to mul-
tiple pathogens, GBD 2010 assigned the COD probabilis-
tically, based on the known etiologic fractions, whereas
CHERG’s scaling approach effectively made each of the
multiple organisms found, equally likely to have caused
that disease. The latter assumption may be problematic,
as CHERG has acknowledged, and efforts should continue
to appropriately assign COD [10]. For diarrhea specifically,
priority should be given to studies that include a control
group or quantify pathogen load to better ascertain the
true etiology of diarrhea.
Conclusions and recommendations
GBD 2010 and CHERG’s mortality estimates represent
enormous undertakings by some of the world’s leading
experts in mortality estimation, yet these separate efforts
resulted in markedly different estimates for country-level
and etiology-specific U5 mortality for pneumonia and
diarrhea. The differences in the estimates highlight firstly
that limited data available for estimating causes of death,
and secondly that decisions on how models are parame-
terized can have important effects on estimates. Given
these two realities, greater openness and transparency is
needed in all aspects of the modeling process, including
timely access to all publically available data sources.
CHERG included a list of sources with their publica-
tions. Access to all sources used in the GBD 2010 study
was not initially provided, but has since been madeavailable on the IHME website via an online visualization
tool: http://viz.healthmetricsandevaluation.org. In addition
to timely access to sources, it is important to publish the
covariates considered for each model (in addition to the
final covariates used), any data processing employed, and
when useful, interim model results. Transparency of
methods and easy access to source data, best represented
in the Rudan et al. estimates of pneumonia etiologies, are
key to maintaining quality and accuracy in data used to in-
form our public health decision-making [9]. Guidelines,
similar to those used for reporting epidemiological studies
(e.g., STROBE and CONSORT), are needed for reporting
modeling work.
Unfortunately, even the “best” current data are problem-
atic due to inherent difficulties in determining the causa-
tive agent for a high proportion of cases, even under
optimal conditions using the best laboratory methods.
The lack of high-quality data necessitated several assump-
tions and reliance on covariates for building the models.
Currently, the countries experiencing the greatest mortal-
ity due to pneumonia and diarrhea have the weakest VR
systems, and very few, if any, VA studies conducted in the
past 30 years. While the improvement of VR systems and
the corresponding collection of COD data for all citizens
are the goal for every country, the necessary infrastructure
investments make this unachievable in the short-term. As
more data are needed specifically from high mortality
countries and underrepresented high-risk groups, VA and
other field-based approaches that can be validated with
shared datasets should be prioritized.
Having varying estimates from multiple modeling
groups can be beneficial for both the scientific and
policy-making communities. Through the comparison of
modeling approaches and estimates, we improve our un-
derstanding of how specific assumptions, inclusion of
different risk factors, and mortality and etiology data
sources influence each model’s estimates. However, a
framework for understanding drivers of differences and
transparency in data sourcing and processing is a
prerequisite.
In October 2013, the BMGF convened an expert meet-
ing in order to better understand the discrepancies be-
tween the estimates discussed in this paper and to
discuss emerging innovations, plans for coordination,
and specific improvements to the models, which could
be used to create future mortality estimates. Members of
IHME, CHERG, and other experts are committed to fur-
ther investigation into the drivers of the differences by sys-
tematically altering the data and covariates included in the
models to test the extent of their influence. IHME specif-
ically agreed to conduct sensitivity analyses excluding VR
data from the model in similar patterns used by CHERG
to demonstrate whether the use of this VR data explains
the differences in the estimates or if the differences are
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previously shared estimates and most of their study input
data, and plans to make publically available more de-
tailed information on the model covariates and model-
ing process. The group also discussed the merits of
moving away from calculating explicit pneumonia and
diarrhea etiologic fractions, with high uncertainty biases,
towards a counterfactual approach, which allows for as-
sessment of the impact of specific interventions by ap-
proximating what would be observed in the absence of
that intervention. IHME determined to use the counter-
factual approach for estimating mortality from pathogens
due to specific etiologies to overcome bias of other
methods in GBD 2.0. This approach will estimate the
reduction in deaths if we removed an individual eti-
ology from the globe. Lastly, the meeting attendees
committed themselves to future collaboration, affirming
the value of face-to-face meetings to harmonize as-
sumptions and share methodologies before publica-
tions. The newly-formed Reference Group for Health
Statistics hosted by WHO and the Independent Advis-
ory Committee for GBD studies will serve as critical
forums to share approaches, assess utility, and ensure
innovation and advancement of quality data. As IHME
released GBD 2013 in late 2014 and CHERG released
new 2012-based estimates in late 2014, deeper under-
standing will improve our interpretation of estimates,
empowering governments, non-governmental organiza-
tions, and the broader international community to ap-
propriately prioritize health interventions and make
more efficient progress toward achieving the Millen-
nium Development Goals.
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